Epinastine
From Wikipedia, the free encyclopedia
 |
|
|---|---|
| Systematic (IUPAC) name | |
| (RS)-3-amino-9,13b-dihydro-1H-dibenz(c,f)imidazo(1,5-a)azepine | |
| Clinical data | |
| AHFS/Drugs.com | monograph |
| MedlinePlus | a604011 |
| Pregnancy cat. | C |
| Legal status | ? |
| Routes | Eye drops |
| Pharmacokinetic data | |
| Protein binding | 64% |
| Half-life | 12 hours |
| Identifiers | |
| CAS number | 80012-43-7 |
| ATC code | R06AX24 S01GX10 |
| PubChem | CID 3241 |
| DrugBank | DB00751 |
| ChemSpider | 3128  |
| UNII | Q13WX941EF |
| KEGG | D07900 |
| ChEBI | CHEBI:51032 |
| ChEMBL | CHEMBL1106 |
| Chemical data | |
| Formula | C16H15N3 |
| Mol. mass | 249.311 g/mol |
| SMILES | eMolecules & PubChem |
|
|
 (what is this?) (verify) |
Epinastine (brand names Alesion, Elestat, Purivist, Relestat) is a second-generation antihistamine and mast cell stabilizer that is used in eye drops to treat allergic conjunctivitis. It is presently produced by Allergan and marketed by Inspire in the United States.[1] It is highly selective for the H1 receptor and does not cross the blood-brain-barrier.[2]
[edit] References
- ^ Pradhan, S; Abhishek, K; Mah, F (2009). "Epinastine: topical ophthalmic second generation antihistamine without significant systemic side effects". Expert opinion on drug metabolism & toxicology 5 (9): 1135–40. doi:10.1517/17425250903117284. PMID 19630694.
- ^ Walther G, Daniel H, Bechtel WD, Brandt K (April 1990). "New tetracyclic guanidine derivatives with H1-antihistaminic properties. Chemistry of epinastine". Arzneimittel-Forschung 40 (4): 440–6. PMID 1972625.
[edit] External links
|
 |
This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it. |
